Shingles Clinical Trial
Official title:
Comparison of Immune Response Induced by Zoster Vaccine According to the Timing of Vaccination After Zoster Illness
The purpose of this study is to determine the optimal timing of zoster vaccination to induce both higher cell-mediated immunity and humoral immunity in adult patients aged over 50 with history of zoster within 5 years.
Zoster vaccination is recommended by FDA for adults aged 60 years or older, and is approved
for people aged 50 through 59 years old. For patients who had shingles, there is no specific
length of time they must wait before receiving shingles vaccine. It is generally recommended
that patients should wait for 6 to 12 months after recovery.
The investigators plan to make scientific recommendation for optimal timing of zoster vaccine
after zoster illness by comparing immune response between two groups (vaccination at 6 months
to 2 years after shingles vs. 2 to 5 years after shingles). Primary outcome is ELISPOT
response at week 6 after vaccination. Secondary outcome is gpELISA titer at week 6 after
vaccination.
All the patients will be asked if they have any contraindications for zoster vaccine by a
physician before vaccination. And they will be monitored for any adverse reaction of the
vaccination after 6 weeks (visiting the hospital).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01132716 -
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions
|
N/A | |
Completed |
NCT01132729 -
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions
|
N/A | |
Completed |
NCT04099706 -
Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT
|
N/A | |
Completed |
NCT04540081 -
Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER Cancer
|
N/A | |
Completed |
NCT01527370 -
Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)
|
Phase 3 | |
Completed |
NCT00534248 -
Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)
|
Phase 3 | |
Completed |
NCT01262300 -
Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents
|
Phase 1 | |
Completed |
NCT00576108 -
A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN)
|
Phase 2 | |
Completed |
NCT00109122 -
Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)
|
Phase 2 | |
Completed |
NCT04047979 -
Systems Biology of Zoster Vaccine
|
Phase 2 | |
Active, not recruiting |
NCT05871541 -
A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
|
Phase 1 | |
Completed |
NCT02114333 -
Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds
|
Phase 1 | |
Completed |
NCT00900783 -
A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster
|
Phase 2 | |
Completed |
NCT01600079 -
ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)
|
||
Active, not recruiting |
NCT02444936 -
ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors
|
Phase 4 | |
Recruiting |
NCT05554068 -
Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
|
Phase 2 | |
Recruiting |
NCT06238726 -
Nudging Patients to Increase Shingles Vaccination
|
N/A | |
Completed |
NCT00300222 -
Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
|
Phase 3 | |
Terminated |
NCT02412917 -
A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia
|
Phase 3 | |
Completed |
NCT00115310 -
Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
|
Phase 3 |